Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program

Gilead Sciences has pulled out of an oral COVID-19 antiviral project, telling Matinas BioPharma that it is focusing on its own approach at the expense of its collaborator’s lipid nanocrystal (LNC) technology platform.